Suparna C. Clasen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Suparna C. Clasen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Chunkit Fung
Division of Hematology and Oncology, Department of Medicine, University of Rochester School of Medicine and Dentistry, James P. Wilmot Cancer Institute, Rochester, USA
3 shared publicationsLois B. Travis
Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
3 shared publicationsHoward D. Sesso
Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
2 shared publications- Aditya Belamkar
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202
1 shared publication Amanda M. Smith
Department of Medicine, Division of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
1 shared publication- Amber Berning
Department of Pathology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
1 shared publication
Latest Publications
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (1) , 4-9
How We Monitor Cardiac Health in Breast Cancer Survivors
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (1) , 4-9
How We Monitor Cardiac Health in Breast Cancer Survivors
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.
- Open Access
- 4 December 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (23) , 102829
SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer
- 4 December 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (23) , 102829
Open AccessSGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer
- Open Access
- 1 August 2024
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 22 (6) , 1
Highlights of the NCCN Oncology Research Program
"Highlights of the NCCN Oncology Research Program" published on Aug 2024 by National Comprehensive Cancer Network.
- 1 August 2024
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 22 (6) , 1
Open AccessHighlights of the NCCN Oncology Research Program
"Highlights of the NCCN Oncology Research Program" published on Aug 2024 by National Comprehensive Cancer Network.
- 3 March 2023
- Published by Springer Nature in Current Oncology Reports
- Vol. 25 (5) , 445-454
Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment
Purpose of Review Testicular cancer (TC) is the leading cancer in men between 18 and 39 years of age. Current treatment involves tumor resection followed by surveillance and/or one or more lines of cisplatin-based chemotherapy (CBCT) and/or bone marrow transplant (BMT). Ten years after treatment, CBCT has been associated with significant atherosclerotic cardiovascular disease (CVD) including myocardial infarction (MI), stroke, and heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome (MetS). Additionally, low testosterone levels and hypogonadism contribute to MetS and may further drive CVD. Recent Findings CVD in TCS has been associated with worse physical functioning accompanied by role limitations, decreased energy, and decreased overall health. Exercise may play a role in ameliorating these effects. Summary Systematic CVD screening practices are needed at TC diagnosis and in survivorship. We encourage a multidisciplinary partnership between primary care physicians, cardiologists, cardio-oncologists, medical oncologists, and survivorship providers to address these needs.
- 3 March 2023
- Published by Springer Nature in Current Oncology Reports
- Vol. 25 (5) , 445-454
Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment
Purpose of Review Testicular cancer (TC) is the leading cancer in men between 18 and 39 years of age. Current treatment involves tumor resection followed by surveillance and/or one or more lines of cisplatin-based chemotherapy (CBCT) and/or bone marrow transplant (BMT). Ten years after treatment, CBCT has been associated with significant atherosclerotic cardiovascular disease (CVD) including myocardial infarction (MI), stroke, and heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome (MetS). Additionally, low testosterone levels and hypogonadism contribute to MetS and may further drive CVD. Recent Findings CVD in TCS has been associated with worse physical functioning accompanied by role limitations, decreased energy, and decreased overall health. Exercise may play a role in ameliorating these effects. Summary Systematic CVD screening practices are needed at TC diagnosis and in survivorship. We encourage a multidisciplinary partnership between primary care physicians, cardiologists, cardio-oncologists, medical oncologists, and survivorship providers to address these needs.
- 27 April 2022
- Published by Springer Nature
- p. 111-121
Carcinoid Heart Disease
- 26 March 2022
- Published by Springer Nature in Current Oncology Reports
- Vol. 24 (7) , 943-950
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge
Purpose of Review Fluoropyrimidine (FDP) chemotherapy regimens used in the treatment of solid tumors such as breast, gastrointestinal, and hepatobiliary malignancies have led to significant survival benefits. However, FDP cardiotoxicity can lead to premature termination of FDP-based chemotherapy treatments. Resuming these crucial therapies after initial FDP cardiotoxicity can be challenging for patients and healthcare providers. Recent Findings Symptomatic cardiotoxicity occurs in up to 35% of patients treated with FDP-based chemotherapy. The most common symptom is chest pain, but palpitations, dyspnea, myocardial infarction, cardiogenic shock, and cardiac arrest can also occur. Several large studies have attempted to discern clinical and genetic risk factors in those who develop FDP cardiotoxicity. With cardiac risk factor optimization and aggressive pre-treatment with anti-anginal agents, rechallenging with FDP is possible and allows patients to resume optimal cancer-directed treatment. Summary FDP cardiotoxicity remains a poorly understood identity. We highlight several recent publications attempting to define the risk factors associated with developing FDP cardiotoxicity. The management of FDP cardiotoxicity and consideration of rechallenge of FDP-based regimens highlights the importance of a multidisciplinary partnership between oncologists and cardiologists/cardio-oncologists.
- 26 March 2022
- Published by Springer Nature in Current Oncology Reports
- Vol. 24 (7) , 943-950
Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge
Purpose of Review Fluoropyrimidine (FDP) chemotherapy regimens used in the treatment of solid tumors such as breast, gastrointestinal, and hepatobiliary malignancies have led to significant survival benefits. However, FDP cardiotoxicity can lead to premature termination of FDP-based chemotherapy treatments. Resuming these crucial therapies after initial FDP cardiotoxicity can be challenging for patients and healthcare providers. Recent Findings Symptomatic cardiotoxicity occurs in up to 35% of patients treated with FDP-based chemotherapy. The most common symptom is chest pain, but palpitations, dyspnea, myocardial infarction, cardiogenic shock, and cardiac arrest can also occur. Several large studies have attempted to discern clinical and genetic risk factors in those who develop FDP cardiotoxicity. With cardiac risk factor optimization and aggressive pre-treatment with anti-anginal agents, rechallenging with FDP is possible and allows patients to resume optimal cancer-directed treatment. Summary FDP cardiotoxicity remains a poorly understood identity. We highlight several recent publications attempting to define the risk factors associated with developing FDP cardiotoxicity. The management of FDP cardiotoxicity and consideration of rechallenge of FDP-based regimens highlights the importance of a multidisciplinary partnership between oncologists and cardiologists/cardio-oncologists.
- Open Access
- 10 October 2021
- Published by Springer Nature in Cardio-Oncology
- Vol. 7 (1) , 1-3
Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms
Significantly increased risks of cardiovascular disease occur in testicular cancer survivors given cisplatin-based chemotherapy. The postulated mechanism of platinum-based chemotherapy’s vascular toxicity has been thought secondary to its different early- and late- effects on vascular injury, endothelial dysfunction, and induction of a hypercoagulable state. We highlight for the first time the similarities between platinum-associated vascular adverse events and the vascular toxicity associated with other xenobiotic-metal contaminants. The vascular toxicity seen in large epidemiologic studies of testicular cancer survivors may in part be similar and mechanistically linked to the risk seen in environmental heavy metal contaminants linked to cardiovascular disease. Future research should be directed to better understand the magnitude of the adverse cardiovascular effects of platinum and to elucidate the underlying mechanisms of action.
- 10 October 2021
- Published by Springer Nature in Cardio-Oncology
- Vol. 7 (1) , 1-3
Open AccessCisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms
Significantly increased risks of cardiovascular disease occur in testicular cancer survivors given cisplatin-based chemotherapy. The postulated mechanism of platinum-based chemotherapy’s vascular toxicity has been thought secondary to its different early- and late- effects on vascular injury, endothelial dysfunction, and induction of a hypercoagulable state. We highlight for the first time the similarities between platinum-associated vascular adverse events and the vascular toxicity associated with other xenobiotic-metal contaminants. The vascular toxicity seen in large epidemiologic studies of testicular cancer survivors may in part be similar and mechanistically linked to the risk seen in environmental heavy metal contaminants linked to cardiovascular disease. Future research should be directed to better understand the magnitude of the adverse cardiovascular effects of platinum and to elucidate the underlying mechanisms of action.
- 1 April 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (5) , 1301-1310
Early Cardiac Effects of Contemporary Radiation Therapy in Patients With Breast Cancer
- 1 April 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (5) , 1301-1310
Early Cardiac Effects of Contemporary Radiation Therapy in Patients With Breast Cancer
- 1 May 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (13) , 1497-1498
Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer
- 1 May 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (13) , 1497-1498
Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer